WO2002080933A1 - A drug for use in bone grafting - Google Patents
A drug for use in bone grafting Download PDFInfo
- Publication number
- WO2002080933A1 WO2002080933A1 PCT/AU2002/000412 AU0200412W WO02080933A1 WO 2002080933 A1 WO2002080933 A1 WO 2002080933A1 AU 0200412 W AU0200412 W AU 0200412W WO 02080933 A1 WO02080933 A1 WO 02080933A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bone
- drug
- bone graft
- bisphosphonate
- patient
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 239
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 229940079593 drug Drugs 0.000 title claims abstract description 62
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 112
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract description 111
- 239000004606 Fillers/Extenders Substances 0.000 claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 43
- 230000002138 osteoinductive effect Effects 0.000 claims abstract description 28
- 230000000278 osteoconductive effect Effects 0.000 claims abstract description 26
- 230000037396 body weight Effects 0.000 claims description 30
- 210000001185 bone marrow Anatomy 0.000 claims description 27
- 238000001356 surgical procedure Methods 0.000 claims description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 15
- 239000011575 calcium Substances 0.000 claims description 14
- 229910052791 calcium Inorganic materials 0.000 claims description 14
- 230000007547 defect Effects 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 11
- 238000003306 harvesting Methods 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000004568 cement Substances 0.000 claims description 9
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 7
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 6
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 6
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 6
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 6
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 6
- 208000037873 arthrodesis Diseases 0.000 claims description 6
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229940019375 tiludronate Drugs 0.000 claims description 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 5
- 206010017076 Fracture Diseases 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 5
- 102000013275 Somatomedins Human genes 0.000 claims description 5
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims description 5
- 229940062527 alendronate Drugs 0.000 claims description 5
- 229960002286 clodronic acid Drugs 0.000 claims description 5
- 229940009626 etidronate Drugs 0.000 claims description 5
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 5
- 229940015872 ibandronate Drugs 0.000 claims description 5
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims description 5
- 229950006971 incadronic acid Drugs 0.000 claims description 5
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 claims description 5
- 229950011129 minodronic acid Drugs 0.000 claims description 5
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims description 5
- 229950010733 neridronic acid Drugs 0.000 claims description 5
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical group NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 5
- 229940046231 pamidronate Drugs 0.000 claims description 5
- -1 putty Substances 0.000 claims description 5
- 229940089617 risedronate Drugs 0.000 claims description 5
- 208000010392 Bone Fractures Diseases 0.000 claims description 4
- 206010065687 Bone loss Diseases 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 3
- 239000001828 Gelatine Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 102000004067 Osteocalcin Human genes 0.000 claims description 3
- 108090000573 Osteocalcin Proteins 0.000 claims description 3
- 206010031252 Osteomyelitis Diseases 0.000 claims description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 238000011882 arthroplasty Methods 0.000 claims description 3
- 230000037416 cystogenesis Effects 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000003044 Closed Fractures Diseases 0.000 claims description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 claims description 2
- 208000002565 Open Fractures Diseases 0.000 claims description 2
- 208000003076 Osteolysis Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000956 alloy Substances 0.000 claims description 2
- 229910045601 alloy Inorganic materials 0.000 claims description 2
- 208000022662 congenital pseudoarthrosis of the fibula Diseases 0.000 claims description 2
- 208000022628 congenital pseudoarthrosis of the tibia Diseases 0.000 claims description 2
- 210000002082 fibula Anatomy 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 2
- 210000004373 mandible Anatomy 0.000 claims description 2
- 210000002050 maxilla Anatomy 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 210000003625 skull Anatomy 0.000 claims description 2
- 239000010936 titanium Substances 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- IWLDTXOHXPDPQG-UHFFFAOYSA-L disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-3-pyrrolidin-1-ylpropyl]phosphinate Chemical compound [Na+].[Na+].OP(=O)(O)C(P([O-])([O-])=O)(O)CCN1CCCC1 IWLDTXOHXPDPQG-UHFFFAOYSA-L 0.000 claims 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 44
- 230000011164 ossification Effects 0.000 description 23
- 239000001175 calcium sulphate Substances 0.000 description 18
- 235000011132 calcium sulphate Nutrition 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 10
- 239000001506 calcium phosphate Substances 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 7
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000002591 computed tomography Methods 0.000 description 7
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 7
- 235000019731 tricalcium phosphate Nutrition 0.000 description 7
- 229940078499 tricalcium phosphate Drugs 0.000 description 7
- 229940112869 bone morphogenetic protein Drugs 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229960004276 zoledronic acid Drugs 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 4
- 210000003692 ilium Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 239000005312 bioglass Substances 0.000 description 3
- 210000001564 haversian system Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- NEAHTABRXFKZGG-UHFFFAOYSA-N 2-pyridin-4-yl-3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=CC(C=2NC3=CN=CC=C3N=2)=C1 NEAHTABRXFKZGG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000112853 Arthrodes Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000017234 Bone cyst Diseases 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 208000002607 Pseudarthrosis Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000027879 direct ossification Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000012829 orthopaedic surgery Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 208000028528 solitary bone cyst Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates to a drug for use in bone healing. More specifically, the present invention relates to the use of bisphosphonates to increase the osteoinductive and/or osteoconductive potential of bone grafts, bone marrow and bone graft substitutes or extenders.
- Bone grafting is a standard technique in orthopaedic surgery, plastic surgery and neurosurgery.
- the object of bone grafting is to enable healing of bony defects, either to restore bony integrity or create bone bridging between bones such as in spinal or other arthrodeses.
- Spinal arthrodesis is a common technique requiring bone grafting for which ample autogenous bone graft (bone graft obtained from the patient him/herself) is sometimes lacking. In instances where the autogenous bone graft is lacking, bone graft substitutes or extenders must be used. It is estimated that 500,000 spinal fusions are performed in the USA annually.
- Bone graft substitute or extender which facilitates the use of less bone graft.
- the cage takes the load while the bone heals.
- Further indications for bone grafting include destruction of bone by tumour or bone cyst formation, the surgical removal of tumorous bone, osteomyelitis, bone defects around arthritic joints (geodes), bone implants, joint replacement prostheses and dental prostheses.
- Autogenous bone grafting remains the preferred standard procedure.
- the procedure involves the use of small amounts of the patient's bone available at the operative site or from a donor site such as the ilium.
- morbidity related to the donor site at the iliac crest has been estimated at as high as 30% and is quite painful in most cases.
- bone graft substitutes are considered to include any physical material other than autogenous bone graft used with the intention of increasing bone formation or bone healing in vivo.
- a graft extender is similar to a graft substitute, and may in fact be identical in composition to a substitute.
- An extender may be used in conjunction with autogenous graft to make the graft "go further".
- bone graft substitutes and extenders include, but are not limited to, calcium hydroxyapatite (Pro-Osteon ®, Pyrost ®), calcium sulphate (Osteoset ®, Bone PlastTM, JaxTM) porous tricalcium phosphate (Vitoss TM)and Bioglass ® (a combination of silicon, sodium, calcium and phosphorus).
- Pro Osteon® 200R is a resorbable, osteoconductive matrix consisting of hydroxyapatite and calcium carbonate.
- Tricalcium Phosphate cement Norian ® SRSTM , alpha-BSMTM
- Most of these products fully resorb fully in vivo, which is a preferred feature of the present invention but in some cases, the resorption of the calcium complex is incomplete. In such cases, the osseointegrated product is typically biocompatible such that this has no clinical consequence.
- Demineralised bone matrix in a gel, putty, sheet or other forms are available.
- the demineralised bone still contains some of the mediators implicated in bone healing and is typically taken from allograft (human bone from a cadaver processed such that infective agents are eliminated) or xenograft (bone or other tissue from an animal source) which has had the calcium removed. This process often leaves many of the gene products (proteins) known to upregulate bone formation in the graft substitute.
- Bone Morphogenetic Protein 2 and other Bone Morphogenetic proteins are available, but these are expensive osteoinductive agents.
- Other products using transforming growth factor beta (TGF- ⁇ ), Fibroblast Growth Factor (FGF) and Insulin-like Growth factor (IGF) are in development.
- TGF- ⁇ transforming growth factor beta
- FGF Fibroblast Growth Factor
- IGF Insulin-like Growth factor
- autogenous bone marrow contains osteoprogenitor stem ceils, it is often used to augment the osteoinductive cellular response to bone grafting.
- osteoprogenitor stem cells can be identified from the harvested marrow and cultured in vitro. A large number of autogenous stem cells may then be transferred back into the operative site in a process known as stem cell transfer.
- the bone marrow and bone forming cells may be administered simply as harvested or, alternatively, admixed with a carrier.
- the present invention consists in a drug selected from the group consisting of at least one bisphosphonate when used for treating a patient requiring bone grafting.
- the present invention consists in a drug selected from the group consisting of at least one bisphosphonate when used for improving the osteoinductive and/or osteoconductive potential of a bone graft.
- the present invention consists in a drug selected from the group consisting of at least one bisphosphonate when used for improving the osteoinductive and/or osteoconductive potential of bone graft substitutes or extenders.
- the present invention consists in a drug selected from the group consisting of at least one bisphosphonate when used for improving the osteoinductive and/or osteoconductive potential of bone graft substitutes or extenders when said bone graft substitutes or extenders are used in combination with a bone graft or with each other.
- the invention consists in a method of performing a bone graft procedure including the step of administering to a patient a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate.
- the invention consists in a method of performing bone grafting in a patient, said method including the steps of:
- the present invention consists in a method of performing bone grafting in a patient, said method including the steps of:
- the present invention consists in a drug selected from the group consisting of at least one bisphosphonate when used for improving the osteoinductive potential of autogenous bone marrow.
- the bone marrow may be harvested from the patient for implantation into the graft site.
- the bone marrow may be admixed with a therapeutically effective amount of at least one bisphosphonate prior to implantation.
- the bone marrow and bisphosphonate may further be mixed with a resorbable carrier of the type described above.
- the bone marrow may also be admixed with autogenous bone graft, bone graft substitutes or extenders in addition to the bisphosphonate before implantation into the graft site.
- the bone marrow is processed following its harvest and the bone stem cells in the marrow caused to multiply.
- the stem cells derived from the bone marrow are then implanted into the graft site.
- Stem cells may also be harvested from some other site, e.g. muscle or fat.
- the bone marrow or cells in addition to being admixed with a therapeutically effective amount of bisphosphonate may further be admixed with nutrients required by cells involved in bone formation or other cells.
- the present invention consists in a method of performing bone grafting in a patient, said method including the steps of:
- the bone graft is typically autogenous bone graft, that is, small pieces of bone harvested from the patient subject of the bone grafting procedure.
- This bone may be harvested from the operative site or percutaneously from a donor site such as the ilium.
- a donor site such as the ilium.
- an open approach to the ilium or other donor site may be used to harvest the graft.
- the bone graft may include allograft (human bone from a cadaver which is processed such as to remove any infectious agents) or xenograft (bone from an animal source).
- said extender is preferably any material other than autogenous bone graft which is adapted to increase the amount of graft material for implantation or injection into a graft site.
- Preferably synthetic calcium complexes are used as extenders.
- extenders include, but are not limited to, calcium hydroxyapatite (Pro-Osteon ®, Pyrost ®), calcium sulphate (Osteoset ® and Bone PlastTM) porous tricalcium phosphate (Vitos TM)and Bioglass ® (a combination of silicon, sodium, calcium and phosphorus).
- Pro Osteon® 200R is a resorbable, osteoconductive matrix consisting of hydroxyapatite and calcium carbonate.
- Tricalcium Phosphate cement (Norian ®) is also available in an injectable form. Most of these products fully resorb fully in vivo, which is a preferred feature of the present invention but in some cases, the resorption of the calcium complex is incomplete. In such cases, the osseointegrated product is typically biocompatible such that this has no clinical consequence.
- the extender may be mixed with other pharmacologically active substances such as antibiotics.
- the bone graft substitute is preferably any material other than autogenous bone graft.
- suitable bone graft substitutes include, but are not limited to, calcium hydroxyapatite (Pro-Osteon ®, Pyrost ®), calcium sulphate (Osteoset ® , Bone PlastTM and JAXTM), porous tricalcium phosphate (Vitoss TM), Bioglass ® (a combination of consisting of silicon, sodium, calcium and phosphorus), Pro Osteon® 200R (resorbable, osteoconductive matrix consisting of hydroxyapatite and calcium carbonate) and Monocalcium and tricalcium phosphate, calcium carbonate and liquid sodium phosphate cement (Norian ® SRSTM), or other injectable calcium phosphate substitute ( eg Alpha-BSMTM).
- the osseointegrated product is preferably biocompatible such that this has no clinical consequence.
- other pharmacologically active substances may be included with the bone graft substitute such as antibiotics.
- the bone graft substitutes or extenders may also contain gene products known to be implicated in bone healing.
- suitable gene products include, but are not limited to, Bone Morphogenetic Protein 7 (OP1), BMP-2 and -4 and -6, other bone morphogenetic proteins, transforming growth factor beta, fibroblast growth factor, insulin-like growth factor, osteocalcin, or other known biologically active proteins, polypeptides, or gene products.
- the at least one bisphosphonate is admixed locally at a graft site with the bone graft or the bone graft substitute or the extender or a combination thereof.
- the at least one bisphosphonate is admixed with the bone graft or bone graft substitute or extender prior to a bone grafting procedure and the admixture administered to the graft site thereafter.
- the bone graft substitute or extender is manufactured to include a therapeutically effective amount of the at least one bisphosphonate.
- the amount of bisphosphonate in the manufactured bone graft substitute or extender is such that new host bone formation is enhanced without substantially interfering with the gradual resorption of the said bone graft substitute or extender (or when used in conjunction with bone graft, the bone graft), such that the bone graft substitute, extender or bone graft together with any carrier medium is completely resorbed and replaced by normal remodelled host bone in the long term.
- the bone graft, the bone graft substitute or the extender or a combination thereof may be administered to the graft site as a first step and the at least one bisphosphonate administered systemically to the patient thereafter.
- the at least one bisphosphonate may also be directly administered to a graft site following administration of the bone graft, the bone graft substitute or the extender or a combination thereof.
- the at least one bisphosphonate may be delivered systemically before the bone graft, the bone graft substitute or the extender is administered to the graft site. Furthermore, the at least one bisphosphonate may be given intra-operatively such that the bone graft, the bone graft substitute or the extender or a combination thereof may be administered to the graft site simultaneously with systemic bisphosphonate administration.
- the at least one bisphosphonate may be administered intravenously although it is also envisaged that the bisphosphonate may be administered orally. Further, the at least one bisphosphonate may be administered subcutaneously, intramuscularly, transdermally, topically or by any other parenteral route by which it can produce its systemic effect. Combinations of these routes are also envisaged.
- the bisphosphonate is zoledronic acid (zoledronate) ⁇ 1 -hydroxy-2-[(1 H-imidazol-1 -yl)ethylidine] bisphosphonic acid ⁇ .
- the bisphosphonate may be, but is not limited to, any one of the following: pamidronate ⁇ 3-amino-1-hydroxypropylidene bisphosphonic acid ⁇ ; alendronate ⁇ 4-amino-1- hydroxybutylidene bisphosphonic acid ⁇ ; etidronate ⁇ 1-hydroxyethylidene bisphosphonic acid ⁇ ; clodronate ⁇ dichloromethylene bisphosphonic acid ⁇ ; risedronate ⁇ 2-(3-pyridinyl)-1-hydroxyethylidene bisphosphonic acid ⁇ ; tiludronate ⁇ chloro-4-phenylthiomethylidene bisphosphonic acid ⁇ ; ibandronate ⁇ 1 -hydroxy-3(methylpentylamin
- zoledronic acid (zoledronate) is administered parenterally at 0.01 to 0.5 mg/kg body weight per dose.
- other bisphosphonates may be administered parenterally as follows: pamidronate at 0.01 to 3.0 mg/kg body weight per dose; ibandronate at 0.01 to 0.5 mg/kg body weight per dose; risedronate at 0.01 to 0.5 mg/kg body weight per dose; alendronate at 0.01 to 5.0 mg/kg body weight per dose; clodronate at 0.01 to 20 mg/kg body weight per dose; etidronate at 0.01 to 20 mg/kg body weight per dose; tiludronate at 0.01 to 5.0 mg/kg body weight per dose; incadronate at 0.01 to 5.0 mg/kg body weight per dose; minodronate at 0.01 to 0.5 mg/kg body weight per dose; olpadronate at 0.01 to 0.5 mg/kg body weight per dose; neridronate at 0.01 to 5.0 mg/kg body weight per dose; EB-153 at 0.01 to 5.0 mg/kg body weight per dose.
- bisphosphonates may be administered orally: zoledronic acid (zoledronate), pamidronate, risedronate, ibandronate, minodronate, alendronate, tiludronate, incadronate, olpadronate, neridronate, clodronate, etidronate, tiludronate or EB-1 -53; wherein said bisphosphonates are administered in doses from 0.01 to 5 mg/kg body weight daily, or the equivalent doses given second daily or weekly.
- the bisphosphonate is initially administered parenterally, followed by oral administration of the bisphosphonate wherein the oral bisphosphonate is administered in a dose from 0.01 to 5 mg/kg body weight daily, or the equivalent dose given second daily or weekly.
- zoledronic acid (zoledronate) is admixed with bone graft or a bone graft substitute or an extender or combinations thereof at 0.0001 to 0.5 mg/kg body weight per dose.
- the zoledronic acid (zoledronate) may be directly applied at the time of surgery or have been incorporated in the manufacturing process of the bone graft substitute or extender.
- bisphosphonates may be admixed with bone graft or a bone graft substitute or an extender or combinations thereof as follows: pamidronate, preferably administered at 0.0001 to 3.0 mg/kg body weight per dose ibandronate (ibandronic acid) preferably administered at 0.0001 to 0.5 mg/kg body weight per dose; risedronate preferably administered at 0.0001 to 0.5 mg/kg body weight per dose; alendronate, preferably administered at 0.0001 to 5.0 mg/kg body weight per dose; clodronate, preferably administered at 0.0001 to 20 mg/kg body weight per dose; etidronate, preferably administered at 0.0001 to 20 mg/kg body weight per dose; tiludronate, preferably administered at 0.0001 to 5.0 mg/kg body weight per dose; minderonate, preferably administered at 0.0001 to 5.0 mg/kg body weight per dose; minodronate, preferably administered at 0.0001 to 0.5 mg/kg body weight per dose; olpadron
- Autogenous bone graft may be harvested percutaneously from a donor site of the patient by way of a bone trocar or other percutaneous bone harvesting device. Alternatively, small amounts of autogenous bone graft may be readily harvested from the operative site. Following either means of harvest, the autogenous bone graft may be mixed with a therapeutically effective amount of bisphosphonate and the mixture subsequently implanted or injected into the graft site to enhance host bone formation at the graft site while still allowing resorption of the autogenous bone graft by the host such that normal remodelled bone fills the graft site in the long term.
- bone graft, a bone graft substitute, an extender or a combination thereof in addition to being admixed with an effective amount of bisphosphonate may be further mixed with a carrier medium such as collagen, gelatine, glycerol, resin, polyglycolic acid, polylactic acid, or any other fully resorbable biocompatible medium, or a combination thereof, either in the form of injectable liquid, gel, putty or cement or in the form of mouldable liquid, cement, putty, gel, flexible sheets, mesh or sponge or other readily applicable method.
- a carrier medium such as collagen, gelatine, glycerol, resin, polyglycolic acid, polylactic acid, or any other fully resorbable biocompatible medium, or a combination thereof, either in the form of injectable liquid, gel, putty or cement or in the form of mouldable liquid, cement, putty, gel, flexible sheets, mesh or sponge or other readily applicable method.
- the carrier may contain nutrients required by cells involved in bone formation or other cells and is preferably resorbable.
- the carrier may further contain gene products known to be implicated in bone healing. Examples of suitable gene products include, but are not limited to, Bone Morphogenetic Protein 7 (OP-1 ), BMP-2,-4 or -6 or other bone morphogenetic proteins, transforming growth factor beta, fibroblast growth factor, insulin-like growth factor, osteocalcin, or other known biologically active proteins, polypeptides, or gene products.
- OP-1 Bone Morphogenetic Protein 7
- BMP-2,-4 or -6 or other bone morphogenetic proteins include, but are not limited to, Bone Morphogenetic Protein 7 (OP-1 ), BMP-2,-4 or -6 or other bone morphogenetic proteins, transforming growth factor beta, fibroblast growth factor, insulin-like growth factor, osteocalcin, or other known biologically active proteins, polypeptides, or gene products.
- a carrier medium is used alone with a bisphosphonate.
- the carrier may
- An indication for bone grafting in a patient may be bone loss resulting from trauma including fracture, delayed union or non-union of bone, or bone loss due to infection following open fracture or open treatment of a closed fracture.
- the patient may have a bone defect unrelated to trauma, including, but not limited to tumour or cyst formation, osteolysis from metabolic disorders such as hyperparathyroidism or renal failure, osteomyelitis, or surgical removal of bone.
- the patient has bone defects in the maxilla or the mandible and is undergoing dental or plastic surgical reconstruction.
- the patient has a skull defect.
- the patient has undergone an osteotomy and bone grafting is required to assist bony union.
- the patient may be undergoing an arthrodesis of a joint or joints.
- the patient may be undergoing a spinal arthrodesis (spinal fusion) operation, either posterior or anterior, with or without the use of internal fixation devices, including interbody spinal fusion cages.
- the cages contain autogenous graft, allograft or xenograft.
- the interbody spinal fusion cage may be coated with a bisphosphonate, or mixture of bisphosphonate and any calcium containing compound such as, but not limited to, calcium sulphate, tricalcium phosphate, hydroxyapatite.
- the cage may alternatively be filled with bisphosphonate particles or particles of bone graft substitute or extender admixed with a therapeutically effective amount of bisphosphonate.
- the cage may alternatively also contain known mediators of bone formation such as BMP's or TGF-beta or other growth factor or cytokine.
- the patient may receive bisphosphonates systemically, and the cage may be empty or contain any combination of autogenous bone graft, bone graft substitute or extender, or known mediators of bone formation such as BMP's or TGF-beta or other suitable growth factors or cytokines
- the patient may be suffering from congenital pseudarthrosis of the tibia, fibula or other bone, or a related condition.
- the bisphosphonate acts to improve the osteoinductive and/or osteoconductive potential of a graft and reverse the primary disorder of local cell function towards osteogenesis.
- Continued bisphosphonate therapy to contain the pathologic process underlying the disorder and prevent re-fracture and reformation of a pseudarthrosis may be added after union is achieved.
- the patient may be undergoing revision or complicated primary joint arthroplasty, where bone grafting is required.
- the grafts are not of the large structural graft type typically used to support the arthroplasty immediately, but rather morsellised bone grafts collected from reamings locally or impaction bone grafts (morsellised allografts) of the femur or pelvis.
- large structural grafts, or a combination of structural and morsellised grafts may be preferred when used with a therapeutic amount of a bisphosphonate such that the bone is eventually resorbed and replaced with normal host remodelled bone in the long term.
- the patient may require the use of bone graft, bone graft substitutes or extenders to fill an alveolar bone defect around a dental prostheses.
- the present invention consists in a drug selected from the group consisting of bisphosphonates when used for treating a patient requiring a spinal or other joint arthrodesis.
- the drug is used to increase the osteoinductive and/or osteoconductive potential of small particles of graft typically obtained locally at a selected area during surgery.
- the increase in osteoinductive and/or osteoconductive potential of the graft increases the fusion rate of the arthrodesis.
- the bisphosphonate may be administered to the patient parenterally at or near the time of the surgery. This may be followed by a second parenteral dose of bisphosphonate administered from between two to six weeks after the initial surgery.
- the initial parenteral dose of bisphosphonate may be followed by administration of oral bisphosphonates in a daily or second daily or weekly regimen commencing about one to three months after the initial dose for a period of about two months or until sufficient new bone (as assessed by the treating doctor) has been produced.
- bone graft, bone marrow, bone graft substitute or extender, or carrier or combinations thereof may be administered to the patient to increase the fusion rate in an arthodesis.
- the present invention consists in a drug selected from the group consisting of at least one bisphosphonate when used for improving the osteoinductive and/or osteoconductive potential of bone graft, bone graft substitutes or extenders wherein said bone graft, bone graft substitutes or extenders are held within a cage for interbody spinal fusion.
- the cage may be made of titanium or any other biocompatible metal or alloy, or of a resorbable polymer or calcium containing complex.
- the cage may further be coated directly with the bisphosphonate or the bisphosphonate may be given systemically to encourage interbody fusion.
- the bisphosphonate may be administered either alone or in combination with bone graft, allograft, xenograft, bone graft substitutes or extenders, mediators of bone formation or any combination of the above.
- the present invention consists in a device for performing a bone grafting procedure, the device including a first receiving means for receiving any one of bone graft, bone marrow, bone graft substitutes, extenders or carriers or a combination thereof and at least a second receiving means for receiving a drug selected from the group consisting of at least one bisphosphonate, the device further including a mixing means to allow mixing of said drug with said bone graft, bone marrow, bone graft substitutes, extenders, carriers or combination thereof.
- the device of the twelfth aspect may further include a means to allow the mixture to be directly injected or implanted into a graft site of a patient.
- the mixture may be removed from the device and delivered to the graft site as a separate step.
- a therapeutically effective amount of a bisphosphonate is defined as that which will increase the osteoinductive and/or osteoconductive potential of the bone graft, bone graft substitute or extender such that bone formation is increased in both amount and mineralisation, without interfering with the process of eventual resorption of the bone graft, substitute or extender, such that the bone graft, substitute or extender is completely replaced by normal remodelled host bone in the long term.
- the resorption of some of the calcium complex may be incomplete due to its own properties, but the osseointegrated product is biocompatible such that this has no clinical consequence.
- Fig. 1 is a generic formula for one class of bisphosphonates
- Fig. 2 depicts a device for percutaneous bone graft harvesting
- Fig.3 is a CT scan of a calcium sulphate cylinder
- Fig.4 is a set of CT scans at four weeks; and Fig.5 is a set of CT scans at 6 weeks.
- the invention relates to the use of a bisphosphonate with the general formula depicted in Figure 1 wherein R1 is varied to give binding and solubility properties to the bisphosphonate and R2 is varied to give various potencies and other properties to the bisphosphonate.
- the present invention relates to the pharmacological use of bisphosphonates in bone grafting.
- the present inventor has found that bisphosphonates increase the inductive and/or osteoconductive potential of various types of graft components including autogenous bone graft, bone marrow, bone graft substitutes and extenders. Accordingly, when a bisphosphonate is administered to a patient, less graft is required. This is of particular significance in certain embodiments wherein the graft is autogenous bone graft or autogenous bone marrow. As such grafts are harvested from the patient themselves, the harvesting of larger amounts of bone or marrow will cause an undesirable level of pain and discomfort for the patient.
- FIG. 10 An example of a device which may be used to harvest bone graft from a patient is generally depicted as 10 in Figure 2 of the accompanying drawings.
- the device 10 includes a trocar 11 , said trocar having a burr or drill 12 positioned within.
- bone graft is forced up from the ilium 13 of a patient and into the body of the trocar 11 as the burr or drill 12 descends. The bone graft may then be removed from the trocar 11 by way of, for example, a syringe 14.
- Example 1 The following example outlines the process by which the effects of bisphosphonates on potentiating new bone formation in a graft may be observed.
- the effects on bone mineralisation and the mechanical properties are observed in a 10mm tibial defect model in rabbits.
- Three groups of animals tested consist of:
- Vehicle Calcium sulphate and vehicle (saline)
- Bisphosphonate Calcium sulphate and vehicle (saline) and two doses of intravenous bisphosphonate.
- Bisphosphonates and Bone Healing The present inventor has previously performed several successful experiments utilising bisphosphonates to improve new bone formation and reduce stress-shielding osteoporosis in a distraction osteogenesis model in the
- the present experiment uses an 8-week-old NZW rabbit model. A 10mm gap is surgically removed from the tibiae of the rabbits. The bones are held with a M-100 external fixator.
- Cylinders of calcium sulphate were prepared on the day of surgery. Moulds were prepared using a combination of 1.0 ml and 3.0 ml syringes, and the Osteoset poured into the moulds in a sterile environment. The cylinders were removed from the moulds at 12 minutes, and allowed to dry in air for 90 minutes, followed by final drying in a microwave for 30 seconds. Once dry, the cylinders were formed into a standard dimension of 10mm length, with an external diameter of 9mm and with a 3mm diameter internal core. The cylinders weighed 0.8-0.9g. The cylinders were stored in sterile environment until required. A CT scan of a calcium sulphate cylinder is shown in Figure 3.
- the operative field was prepared by shaving with clippers, disinfected with povidone iodine 4% w/v in 70% alcohol.
- the right tibia was exposed sub- periosteally along its length and four 3mm Orthofix pins inserted.
- An M-100 monolateral external fixator (Orthofix S.L.R) was applied.
- a 10 mm piece of mid- diaphyseal tibia was removed using an oscillating saw, along with the central 10 mm of periosteum.
- a calcium sulphate cylinder was then placed in the defect, and held by slight compression of the external fixator.
- the animals were randomised such that at the time of surgery, 24 animals had Osteoset cylinders with saline adsorbed inserted, 12 of whom were given saline-only infusions and 12 of whom were given 0.1 mg/kg zoledronic acid infusion at the time of surgery and again on day 14. A further 12 animals had
- the operative field was irrigated with Normal Saline and then with a solution containing 600mg of Benzyl-penicillin to minimise the risk of infection.
- CT scans were performed at 28 days (18 animals) and at 42 days (18 animals) using a Stratec XCT Research SA pQCT scanner.
- Radiographs showed that the calcium sulphate cylinders were largely dissolved by week 2, and not detectable by week 4. There was a visual trend for improved bone formation at the site of the cylinder in the locally dosed group, but this was difficult to quantify on the plain radiographs, due to variable periosteal bone formation. Quantification was based on the CT scan results.
- the applicant has previously documented improvements in amount, mineral density and strength of bone in a rabbit distraction osteogenesis model when one or two doses of IV zoledronic acid are given.
- This experiment documents that local bisphosphonate administration can favourably alter the amount and density of calcium sulphate mediated bone formation in a bone defect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02712634A EP1383509A4 (en) | 2001-04-03 | 2002-03-28 | A drug for use in bone grafting |
US10/474,072 US20040157798A1 (en) | 2001-04-03 | 2002-03-28 | Drug for use in bone grafting |
AU2002244520A AU2002244520B2 (en) | 2001-04-03 | 2002-03-28 | A drug for use in bone grafting |
NZ528659A NZ528659A (en) | 2001-04-03 | 2002-03-28 | A drug for use in bone grafting |
JP2002578972A JP2004526747A (en) | 2001-04-03 | 2002-03-28 | Drugs used in bone transplantation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR4187 | 2001-04-03 | ||
AUPR4187A AUPR418701A0 (en) | 2001-04-03 | 2001-04-03 | A drug for use in bone grafting |
AUPR9613A AUPR961301A0 (en) | 2001-12-17 | 2001-12-17 | A drug for use in bone grafting |
AUPR9613 | 2001-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002080933A1 true WO2002080933A1 (en) | 2002-10-17 |
Family
ID=25646639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2002/000412 WO2002080933A1 (en) | 2001-04-03 | 2002-03-28 | A drug for use in bone grafting |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040157798A1 (en) |
EP (1) | EP1383509A4 (en) |
JP (1) | JP2004526747A (en) |
AU (1) | AU2002244520B2 (en) |
NZ (1) | NZ528659A (en) |
WO (1) | WO2002080933A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005027921A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
WO2005074944A1 (en) * | 2004-02-10 | 2005-08-18 | Abiogen Pharma S.P.A. | Use of sodium neridronate to promote new bone formation |
JP2006519082A (en) * | 2003-03-05 | 2006-08-24 | ボーン サポート アクチボラゲット | New bone substitute composition |
WO2007041617A2 (en) * | 2005-10-03 | 2007-04-12 | Warsaw Orthopedic, Inc. | Bioactive composite spinal implants |
EP2139507A1 (en) * | 2007-04-27 | 2010-01-06 | Unigene Laboratories, Inc. | Methods and compositions for fostering and preserving bone growth |
US7935121B2 (en) | 2003-11-11 | 2011-05-03 | Bone Support Ab | Device for providing spongy bone with bone substitute and/or bone reinforcing material, bone substitute and/or bone reinforcing material and method |
US7938572B2 (en) | 2004-06-22 | 2011-05-10 | Bone Support Ab | Device for producing a hardenable mass |
US8399023B2 (en) | 2009-07-31 | 2013-03-19 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
WO2013108035A1 (en) * | 2012-01-19 | 2013-07-25 | Depuy International Limited | Bone filler composition |
US8852240B2 (en) | 2004-10-25 | 2014-10-07 | Kieran Murphy, Llc | Methods and compositions for fostering and preserving bone growth |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
WO2016150876A1 (en) * | 2015-03-23 | 2016-09-29 | Bone Support Ab | Biphasic ceramic bone substitute |
US10093691B2 (en) | 2009-07-31 | 2018-10-09 | Grunenthal Gmbh | Crystallization method and bioavailability |
US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
US10294107B2 (en) | 2013-02-20 | 2019-05-21 | Bone Support Ab | Setting of hardenable bone substitute |
WO2019206677A1 (en) * | 2018-04-23 | 2019-10-31 | Seagles Ab | Novel treatment approach by targeted delivery of bioactive molecules bio modulated ceramics |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
US8287596B1 (en) * | 2006-10-11 | 2012-10-16 | Nuvasive, Inc. | Intraoperative surgical barrier and related methods |
EP3181157B1 (en) * | 2006-11-03 | 2019-08-14 | BioMimetic Therapeutics, LLC | Compositions and methods for arthrodetic procedures |
US20100105867A1 (en) * | 2007-03-06 | 2010-04-29 | Takara Bio Inc. | Process for producing osteocalcin-containing extract |
US8882740B2 (en) * | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
US20110307074A1 (en) * | 2010-05-24 | 2011-12-15 | University Of The Witwatersrand, Johannesburg | Biomaterials for use in methods of bone replacement therapy |
CA2830505A1 (en) * | 2011-03-21 | 2012-09-27 | Ronald Childs | Sleeve for bone fixation device |
US10238507B2 (en) | 2015-01-12 | 2019-03-26 | Surgentec, Llc | Bone graft delivery system and method for using same |
DK3359209T3 (en) | 2015-10-05 | 2021-03-15 | Hettwer Holding Aps | Compositions and methods for treatment of bone defects |
US10687828B2 (en) | 2018-04-13 | 2020-06-23 | Surgentec, Llc | Bone graft delivery system and method for using same |
US11116647B2 (en) | 2018-04-13 | 2021-09-14 | Surgentec, Llc | Bone graft delivery system and method for using same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0950417A2 (en) * | 1998-02-23 | 1999-10-20 | Pfizer Products Inc. | Treatment of skeletal disorders |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208219A (en) * | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
EP0523926A3 (en) * | 1991-07-15 | 1993-12-01 | Smith & Nephew Richards Inc | Prosthetic implants with bioabsorbable coating |
CA2151240A1 (en) * | 1992-12-23 | 1994-07-07 | Donna T. Whiteford | Biophosphonate/estrogen therapy for treating and preventing bone loss |
US5403829A (en) * | 1993-03-24 | 1995-04-04 | Leiras Oy | Use of bisphosphonates in endo-osteal bone surgery |
US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
AU5973496A (en) * | 1995-06-06 | 1996-12-24 | Merck & Co., Inc. | Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices |
CA2360319A1 (en) * | 1999-02-09 | 2000-08-17 | Memorial Sloan-Kettering Cancer Center | Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts |
AUPQ232599A0 (en) * | 1999-08-19 | 1999-09-09 | Royal Alexandra Hospital For Children, The | Drug for treating fractures |
HU228400B1 (en) * | 2000-06-20 | 2013-03-28 | Novartis Ag | The use of bisphosphonates for treatment of osteoporosis |
MXPA03007029A (en) * | 2001-02-06 | 2004-10-15 | Royal Alexandra Hosp Children | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis. |
-
2002
- 2002-03-28 AU AU2002244520A patent/AU2002244520B2/en not_active Ceased
- 2002-03-28 WO PCT/AU2002/000412 patent/WO2002080933A1/en not_active Application Discontinuation
- 2002-03-28 NZ NZ528659A patent/NZ528659A/en unknown
- 2002-03-28 US US10/474,072 patent/US20040157798A1/en not_active Abandoned
- 2002-03-28 EP EP02712634A patent/EP1383509A4/en not_active Withdrawn
- 2002-03-28 JP JP2002578972A patent/JP2004526747A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0950417A2 (en) * | 1998-02-23 | 1999-10-20 | Pfizer Products Inc. | Treatment of skeletal disorders |
Non-Patent Citations (8)
Title |
---|
BUCHS N. ET AL: "Allogenic bone marrow transplantation is associated with a preferential femoral neck bone loss", OSTEOPOROSIS INTERNATIONAL, vol. 12, 2001, pages 880 - 886, XP002972557 * |
DINI G. ET AL: "Long-term follow-up of two children with a variant of mild autosomal recessive osteopetrosis undergoing bone marrow transplantation", BONE MARROW TRANSPLANTATION, vol. 26, 2000, pages 219 - 224, XP002972554 * |
INORI F. ET AL: "Possibility of 'distraction arthrogenesis': first report in rabit model", J. ORTHOP. SCI., vol. 6, 2001, pages 585 - 590, XP002972555 * |
KAYNAK D. ET AL: "A histopathological investigation on the effects of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats", J. OF PERIODONTOLOGY, vol. 71, no. 5, May 2000 (2000-05-01), pages 790 - 796, XP002973058 * |
MYOUNG H. ET AL: "Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats", J. PERIODONT. RES., vol. 36, August 2001 (2001-08-01), pages 244 - 251, XP002972551 * |
RAWLINSON P. ET AL: "Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 66, no. 5, May 1991 (1991-05-01), pages 629 - 639, XP002973059 * |
See also references of EP1383509A4 * |
TROMBETTI A. ET AL: "Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar post-transplantation- accelerated bone loss by pamidronate", J. OF HEART AND LUNG TRANSPLANTATION, vol. 19, no. 8, August 2000 (2000-08-01), pages 736 - 743, XP002972556 * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006519082A (en) * | 2003-03-05 | 2006-08-24 | ボーン サポート アクチボラゲット | New bone substitute composition |
JP4805812B2 (en) * | 2003-03-05 | 2011-11-02 | ボーン サポート アクチボラゲット | New bone substitute composition |
JP2007505886A (en) * | 2003-09-19 | 2007-03-15 | ファイザー・プロダクツ・インク | Pharmaceutical compositions and methods comprising combinations of 2-methylene-19-nor-vitamin D derivatives and bisphosphonates |
WO2005027921A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
US7935121B2 (en) | 2003-11-11 | 2011-05-03 | Bone Support Ab | Device for providing spongy bone with bone substitute and/or bone reinforcing material, bone substitute and/or bone reinforcing material and method |
WO2005074944A1 (en) * | 2004-02-10 | 2005-08-18 | Abiogen Pharma S.P.A. | Use of sodium neridronate to promote new bone formation |
US7938572B2 (en) | 2004-06-22 | 2011-05-10 | Bone Support Ab | Device for producing a hardenable mass |
US8297831B2 (en) | 2004-06-22 | 2012-10-30 | Bone Support Ab | Device for producing a hardenable mass |
US8852240B2 (en) | 2004-10-25 | 2014-10-07 | Kieran Murphy, Llc | Methods and compositions for fostering and preserving bone growth |
WO2007041617A2 (en) * | 2005-10-03 | 2007-04-12 | Warsaw Orthopedic, Inc. | Bioactive composite spinal implants |
WO2007041617A3 (en) * | 2005-10-03 | 2008-04-03 | Warsaw Orthopedic Inc | Bioactive composite spinal implants |
EP2139507A1 (en) * | 2007-04-27 | 2010-01-06 | Unigene Laboratories, Inc. | Methods and compositions for fostering and preserving bone growth |
EP2139507A4 (en) * | 2007-04-27 | 2012-06-06 | Unigene Lab Inc | Methods and compositions for fostering and preserving bone growth |
US8933057B2 (en) | 2009-07-31 | 2015-01-13 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US10093691B2 (en) | 2009-07-31 | 2018-10-09 | Grunenthal Gmbh | Crystallization method and bioavailability |
US8399023B2 (en) | 2009-07-31 | 2013-03-19 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US10323052B2 (en) | 2009-07-31 | 2019-06-18 | Grunenthal Gmbh | Crystallization method and bioavailability |
US9334296B2 (en) | 2009-07-31 | 2016-05-10 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
US10519176B2 (en) | 2010-11-24 | 2019-12-31 | Thar Pharma, Llc | Crystalline forms |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
RU2621151C2 (en) * | 2012-01-19 | 2017-05-31 | Депью Интернэшнл Лимитед | Composition of bone filler |
EP3150235A1 (en) * | 2012-01-19 | 2017-04-05 | Depuy International Limited | Bone filler composition |
WO2013108035A1 (en) * | 2012-01-19 | 2013-07-25 | Depuy International Limited | Bone filler composition |
AU2013210877B2 (en) * | 2012-01-19 | 2016-01-07 | Depuy International Limited | Bone filler composition |
CN104105509A (en) * | 2012-01-19 | 2014-10-15 | 德普伊国际有限公司 | Bone filler composition |
US10294107B2 (en) | 2013-02-20 | 2019-05-21 | Bone Support Ab | Setting of hardenable bone substitute |
US10994998B2 (en) | 2013-02-20 | 2021-05-04 | Bone Support Ab | Setting of hardenable bone substitute |
WO2016150876A1 (en) * | 2015-03-23 | 2016-09-29 | Bone Support Ab | Biphasic ceramic bone substitute |
US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
WO2019206677A1 (en) * | 2018-04-23 | 2019-10-31 | Seagles Ab | Novel treatment approach by targeted delivery of bioactive molecules bio modulated ceramics |
EP3903842A1 (en) * | 2018-04-23 | 2021-11-03 | Moroxite AB | Novel treatment approach by targeted delivery of bioactive molecules bio modulated ceramics |
EP3903841A1 (en) * | 2018-04-23 | 2021-11-03 | Moroxite AB | Novel treatment approach by targeted delivery of bioactive molecules bio modulated ceramics |
Also Published As
Publication number | Publication date |
---|---|
NZ528659A (en) | 2005-02-25 |
EP1383509A1 (en) | 2004-01-28 |
AU2002244520B2 (en) | 2007-05-24 |
EP1383509A4 (en) | 2005-10-26 |
US20040157798A1 (en) | 2004-08-12 |
JP2004526747A (en) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002244520B2 (en) | A drug for use in bone grafting | |
AU2002244520A1 (en) | A drug for use in bone grafting | |
JP5368102B2 (en) | Maxillofacial bone enhancement using rhPDGF-BB and biocompatible matrix | |
CA2435552C (en) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis | |
KR101115964B1 (en) | Bone filler loading extended release type drug for treating osteoporosis | |
Toker et al. | A comparative evaluation of the systemic and local alendronate treatment in synthetic bone graft: a histologic and histomorphometric study in a rat calvarial defect model | |
CN105854074B (en) | Composition and method for Distraction Osteogenesis | |
CN108135702A (en) | Implantation material and application method with oxidation sterol drug loading | |
AU2002221339A1 (en) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis | |
JP2004526747A5 (en) | ||
WO2002098307A1 (en) | A device for the delivery of a drug to a fractured bone | |
JP2021151525A (en) | Implants containing oxysterol and methods of using the same | |
US20220023493A1 (en) | Compositions and methods for regeneration of bone tissue | |
MX2012012050A (en) | Methods and compositions for improving implant osseointegration. | |
JP2024037985A (en) | artificial periosteum | |
JP2010526064A (en) | Methods and compositions for nurturing and preserving bone tissue growth | |
JP2023524922A (en) | Compositions for improved fracture healing | |
Pioletti | Using drug delivery systems to enhance joint replacement | |
Jackson | Assessment of the closure of critical sized defects in the rabbit calvarium utilizing demineralized bone matrix putty as an allogenic graft material | |
Sheikh et al. | The Challenge of Predictable Vertical Alveolar Ridge Augmentation for Dental Implant Site Development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002244520 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002578972 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 528659 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002712634 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002712634 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10474072 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 528659 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 528659 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002244520 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002712634 Country of ref document: EP |